ABT:NYE-Abbott Laboratories (USD)

COMMON STOCK | Medical Devices | NYE

Last Closing Price

USD 92.10

Change

+1.34 (+1.48)%

Market Cap

USD 158.28B

Volume

5.18M

Average Target Price

USD 99.84 (+8.40%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. Its Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptom; gynecological disorder; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraine; and anti-infective clarithromycin, as well as provides influenza vaccines and products that regulate physiological rhythm of the colon. The company's Diagnostic Products segment offers core laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automates the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detects and measures infectious agents; cartridges for blood analysis; rapid diagnostics systems for infectious diseases; molecular point-of-care testing for HIV, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test systems, as well as remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. Its Nutritional Products segment provides pediatric and adult nutritional products. The company's Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases, as well as neuromodulation devices for the management of chronic pain and movement disorders. This segment also provides glucose and blood glucose monitoring systems, including test strips, sensors, data management decision software, and accessories for people with diabetes. The company was founded in 1888 and is headquartered in Abbott Park, Illinois.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-05-28 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MDT Medtronic plc

+2.14 (+2.23%)

USD130.20B 26.76 18.03
SYK Stryker Corporation

+3.73 (+1.95%)

USD69.93B 32.74 20.21
BSX Boston Scientific Corporation

+0.33 (+0.89%)

USD50.64B 11.90 42.16
EW Edwards Lifesciences Corporati..

+5.80 (+2.68%)

USD45.87B 41.57 34.09
ZBH Zimmer Biomet Holdings, Inc

-0.35 (-0.27%)

USD26.43B 68.18 24.42
SNN Smith & Nephew plc

+0.93 (+2.27%)

USD17.52B 30.09 14.97
BIO-B Bio-Rad Laboratories, Inc

N/A

USD14.38B 8.93 6.18
BIO Bio-Rad Laboratories, Inc

+6.41 (+1.36%)

USD13.88B 9.04 6.20
PEN Penumbra, Inc

+1.57 (+0.92%)

USD5.73B 163.88 132.38
GMED Globus Medical, Inc

-0.16 (-0.29%)

USD5.31B 38.27 20.07

ETFs Containing ABT

Symbol Name Weight Mer Price(Change) Market Cap
IHI iShares U.S. Medical Devi.. 14.15 % 0.43 %

+4.15 (+1.60%)

USD6.23B
ACT AdvisorShares Vice ETF 6.99 % 0.99 %

-0.09 (-0.37%)

USD9.78M
BOUT Innovator IBD Breakout Op.. 5.90 % 0.84 %

+0.37 (+1.77%)

USD5.10M
PJP Invesco Dynamic Pharmaceu.. 5.66 % 0.56 %

+0.51 (+0.80%)

USD0.36B
LIFE:CA Evolve Global Healthcare .. 5.13 % 0.45 %

+0.16 (+0.77%)

USD0.01B
HHL:CA Harvest Healthcare Leader.. 5.05 % 1.12 %

+0.01 (+0.13%)

USD0.33B
HHL-U:CA Harvest Healthcare Leader.. 5.05 % 1.11 %

+0.09 (+1.17%)

N/A
FTXH First Trust Nasdaq Pharma.. 4.72 % 0.60 %

+0.24 (+1.07%)

USD8.87M
XLV Health Care Select Sector.. 4.51 % 0.13 %

+1.31 (+1.30%)

USD24.65B
ZPDH:F SPDR S&P U.S. Health Care.. 4.22 % 0.15 %

+0.69 (+2.67%)

USD0.23B
IHCU:LSE iShares S&P 500 Healt.. 4.22 % 0.15 %

+19.75 (+3.30%)

USD1.53B
QDVG:XETRA iShares S&P 500 Healt.. 4.22 % 0.15 %

+0.22 (+3.36%)

USD1.53B
QDVG:F iShares S&P 500 Health Ca.. 4.22 % 0.15 %

+0.19 (+2.84%)

USD1.53B
ZPDH:XETRA SPDR S&P U.S. Health .. 4.22 % 0.15 %

+0.84 (+3.24%)

USD0.23B
IYH iShares U.S. Healthcare E.. 4.11 % 0.43 %

+3.03 (+1.41%)

USD2.42B
XUHC:XETRA Xtrackers MSCI USA Health.. 4.04 % 0.12 %

+1.21 (+3.33%)

USD0.52B
XSHC:LSE Xtrackers MSCI USA Health.. 4.04 % 0.12 %

+110.50 (+3.40%)

USD0.52B
SXLV:LSE SPDR S&P U.S. Health Care.. 3.95 % 0.15 %

+1.16 (+4.12%)

USD0.18B
IUHC:LSE iShares S&P 500 Health Ca.. 3.94 % 0.15 %

+0.29 (+3.96%)

USD1.17B
GDNA Goldman Sachs Human Evolu.. 3.87 % 0.50 %

+0.29 (+0.50%)

USD0.02B
PWB Invesco Dynamic Large Cap.. 3.86 % 0.55 %

+0.35 (+0.68%)

USD0.61B
XUHC:LSE Xtrackers MSCI USA Health.. 3.82 % 0.12 %

+1.66 (+4.17%)

USD0.40B
FHLC Fidelity MSCI Health Care.. 3.82 % 0.08 %

+0.58 (+1.17%)

USD1.74B
VHT Vanguard Health Care Inde.. 3.61 % 0.10 %

+2.17 (+1.13%)

USD11.78B
HWF:CA Middlefield Health & Well.. 3.35 % 0.85 %

+0.07 (+0.60%)

USD0.05B
ISUS:LSE iShares MSCI USA Islamic .. 3.14 % 0.50 %

+59.00 (+1.71%)

USD0.07B
IXJ iShares Global Healthcare.. 3.06 % 0.46 %

+1.10 (+1.61%)

USD2.15B
VIG Vanguard Dividend Appreci.. 2.86 % 0.06 %

+0.33 (+0.28%)

USD49.76B
XHC:CA iShares Global Healthcare.. 2.84 % 0.63 %

+0.81 (+1.51%)

USD0.34B
XDWH:XETRA Xtrackers MSCI World Heal.. 2.75 % 0.30 %

+1.03 (+3.02%)

USD0.84B
XDWH:F Xtrackers MSCI World Heal.. 2.75 % 0.30 %

+1.01 (+2.96%)

USD0.84B
ISDU:LSE iShares MSCI USA Islamic .. 2.71 % 0.50 %

+1.04 (+2.47%)

USD0.08B
XDWH:LSE Xtrackers MSCI World Heal.. 2.58 % 0.30 %

+1.47 (+3.93%)

USD0.47B
JHMH John Hancock Multifactor .. 2.58 % 0.40 %

+0.54 (+1.43%)

USD0.04B
WHEA:LSE SPDR MSCI World Health Ca.. 2.56 % 0.30 %

+1.74 (+4.02%)

USD0.30B
CURE Direxion Daily Healthcare.. 2.30 % 1.08 %

+2.06 (+3.70%)

USD0.15B
FTHI First Trust BuyWrite Inco.. 2.03 % 0.85 %

-0.20 (-1.03%)

USD0.06B
XRLV Invesco S&P 500 ex-Rate S.. 1.31 % 0.25 %

+0.11 (+0.31%)

USD0.08B
CHGX Change Finance U.S. Large.. 1.27 % 0.49 %

+0.01 (+0.06%)

USD0.02B
JMIN JPMorgan U.S. Minimum Vol.. 0.75 % 0.12 %

+0.20 (+0.71%)

USD0.09B
RXD ProShares UltraShort Heal.. 0.00 % 0.95 %

-0.36 (-2.61%)

USD1.21M
RXD ProShares UltraShort Heal.. 0.00 % 0.95 %

-0.36 (-2.61%)

USD1.21M
RXL ProShares Ultra Health Ca.. 0.00 % 0.95 %

+3.28 (+2.80%)

USD0.10B
FHI Federated Hermes, Inc 0.00 % 0.00 %

-0.90 (-3.73%)

N/A
HIG:CA Brompton Global Healthcar.. 0.00 % 0.00 %

+0.19 (+2.12%)

USD0.05B
LIFE aTyr Pharma, Inc 0.00 % 0.00 %

-0.21 (-5.36%)

USD0.04B
BSCL Invesco BulletShares 2021.. 0.00 % 0.10 %

-0.04 (-0.19%)

USD1.81B

Market Performance

  Market Performance vs.
Industry/Classification (Medical Devices)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 6.03% 72% C- 90% A-
Dividend Return 0.83% 83% B 40% F
Total Return 6.86% 72% C- 90% A-
Trailing 12 Months  
Capital Gain 21.71% 58% F 89% B+
Dividend Return 1.80% 83% B 43% F
Total Return 23.51% 58% F 89% B+
Trailing 5 Years  
Capital Gain 89.51% 43% F 91% A-
Dividend Return 11.73% 86% B 46% F
Total Return 101.23% 43% F 90% A-
Average Annual (5 Year Horizon)  
Capital Gain 19.33% 45% F 88% B+
Dividend Return 2.21% 100% A+ 50% F
Total Return 21.53% 45% F 88% B+
Risk Return Profile  
Volatility (Standard Deviation) 17.46% 55% F 39% F
Risk Adjusted Return 123.34% 60% D- 86% B
Market Capitalization 158.28B 100% A+ 99% A+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Devices)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 46.20 33% F 11% F
Price/Book Ratio 5.35 25% F 13% F
Price / Cash Flow Ratio 25.79 44% F 9% F
EV/EBITDA 22.60 38% F 14% F
Management Effectiveness  
Return on Equity 11.56% 71% C- 67% D+
Return on Invested Capital 8.34% 76% C 64% D
Return on Assets 4.59% 76% C 74% C
Debt to Equity Ratio 53.59% 45% F 60% D-
Technical Ratios  
Short Ratio 1.47 60% D- 55% F
Short Percent 1.13% 75% C 84% B
Beta 0.97 60% D- 58% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Higly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector